[Therapeutic strategy for XXXX ].

@entity1 @entity5409 @entity5 @entity1804 @entity4614 @entity145 @entity977 @entity976 @entity2010
OBJECTIVE: To make a clear distinction of @entity5409 : craniopharyngioma (CR), @entity1804 ( @entity1804 ), @entity977 (PA) and intrasellar @entity145 ( @entity145 ). METHODS: A total of 72 adult @entity1 underwent transsphenoidal approach for the removal of @entity5409 . The authors conducted a study to (1) investigate preoperative clinical, biochemical and radiographic features of @entity1 with CR, @entity1804 , PA and @entity145 ; (2) identify clinicopathological features of independently predicting recurrence in CR, PA and @entity1804 in adults. These adult @entity1 included CR (n = 10), @entity1804 (n = 27), cystic PA (n = 32) and 1 @entity1 with @entity145 (n = 1). RESULTS: The CR @entity1 presented with @entity4614 in 80% of cases. According to the biochemical criteria, the percentage of @entity1 with a slight prolactin increase happened in PA (55.6%) and @entity1804 (44.4%). Cystic PA had post-contrasting enhancement in cyst wall because of @entity5 tissue. Calcification detectable on computed tomographic scanning was present in 70% of CR @entity1 . It was a significantly greater proportion compared to other diseases. Typical @entity1804 was located between anterior and posterior pituitary and the contents in @entity1804 were variable. Mass effects vanished post-operatively in all kinds of lesions. Long-term hormone replacement therapy was administered more in CR @entity1 (60%) and @entity2010 than other lesions. One PA @entity1 and 2 CR @entity1 had recurrence during a follow-up of 12 - 52 months (mean: 34). @entity1804 and @entity145 had no recurrence. CONCLUSION: @entity976 , @entity1804 , @entity977 and intrasellar @entity145 are a spectrum of diseases with different therapeutic strategies. An accurate diagnosis of these lesions is essential so as to determine the type of treatment to improve outcome.
